Metrics details. Patients were selected by an interdisciplinary team, taking clinical parameters, histopathology from targeted or systematic biopsies, mpMRI and patients preferences into consideration. Patients were thoroughly informed about alternative treatment options and that TULSA is an individual treatment approach. High-intensity ultrasound was applied using an ablation device placed in the prostatic urethra.
Heat-development within the prostatic tissue was monitored using MR-thermometry. Challenges during the ablation procedure and follow-up of oncologic and functional outcome of at least 12 months after TULSA treatment were documented. No major adverse events were documented. PSA values significantly decreased after therapy 2.
Establishment of TULSA in clinical routine was unproblematic, short-term outcome seems to be encouraging. The risk of erectile function impairment requires elaborate information of the patient.
Peer Review reports. Treatment options for localized prostate cancer PCa range from radical prostatectomy, radiation therapy, and focal therapy to active surveillance.
Careful patient selection is the essential task for appropriate oncologic treatment while preserving good life quality. Focal therapies have the potential to provide proper oncologic treatment while preserving urinary continence and erectile function due to a nerve-sparing application [ 1 ].
